LLY news sentiment

#142Tone

finance.yahoo.comDirect company coverage

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales

DowngradeEarningsPharma

Published

12 Aug 2026 17:29

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#230Tone

finance.yahoo.comDirect company coverage

Eli Lilly Stock Falls While Retatrutide Lawsuits Expand

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug

Clinical TrialsLawsuitsObesityPharmaQuarterly Earnings

Published

12 Aug 2026 17:24

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#383Tone

finance.yahoo.comDirect company coverage

Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci's recent early Phase 1 ABS-201 update and Eli Lilly's US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareh

Balance SheetBiotechClinical TrialsShare PriceShareholder

Published

12 Aug 2026 17:11

Catalyst

Deals and strategy

Evidence role

Direct company coverage

Duplicates

1 consolidated

#435Tone

finance.yahoo.comDirect company coverage

Lilly Targets Black-Market Retatrutide Sellers

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi

Clinical TrialsLawsuitsPharmaRegulation

Published

12 Aug 2026 16:54

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#573Tone

finance.yahoo.comDirect company coverage

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo

DiabetesEarningsFourth QuarterGuidanceObesityPharma

Published

12 Aug 2026 15:10

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#650Tone

finance.yahoo.comDirect company coverage

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20

EarningsGuidanceObesityOncologyPharmaRevenue Growth

Published

12 Aug 2026 15:03

Catalyst

Deals and strategy

Evidence role

Direct company coverage

Duplicates

1 consolidated

#771Tone

finance.yahoo.comDirect company coverage

IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point

Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens. Continue Reading

Published

12 Aug 2026 14:29

Catalyst

Market update

Evidence role

Direct company coverage

Duplicates

1 consolidated

#865Tone

finance.yahoo.comDirect company coverage

InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001

IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro

Antibody Drug ConjugatesBiotechCancerClinical Trials

Published

12 Aug 2026 11:30

Catalyst

Market update

Evidence role

Direct company coverage

Duplicates

1 consolidated

#948Tone

finance.yahoo.comDirect company coverage

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors an

Clinical TrialsFda ApprovalHealthcarePharmaRegulation

Published

12 Aug 2026 09:30

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1037Tone

finance.yahoo.comDirect company coverage

Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?

Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, its prolactin receptor antibody, and a US$40 million investment and development support from Eli Lilly that extend its cash runway into the second half of 2028. Next, we'll examine how Eli Lilly's US$40 million investment and advisory role could reshape Absci's investment narrative around ABS-201.

BiotechClinical TrialsEarningsEarnings ReleaseRevenue Growth

Published

12 Aug 2026 07:10

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1147Tone

finance.yahoo.comDirect company coverage

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended Jun

Balance SheetBiotechClinical TrialsFda ApprovalFourth QuarterShares Outstanding

Published

11 Aug 2026 20:05

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1272Tone

finance.yahoo.comDirect company coverage

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator.

Fda ApprovalObesityPharmaRegulation

Published

11 Aug 2026 19:07

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1390Tone

finance.yahoo.comDirect company coverage

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory

BiotechCompetitionEarningsFda ApprovalImmunology

Published

11 Aug 2026 16:54

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1457Tone

finance.yahoo.comDirect company coverage

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo

Fda ApprovalHealthcarePharmaUK Approval

Published

11 Aug 2026 15:12

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1586Tone

finance.yahoo.comDirect company coverage

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa

EarningsInnovative MedicineLitigationMedtechPatent ExpirationShare Price

Published

11 Aug 2026 13:12

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1633Tone

finance.yahoo.comDirect company coverage

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial

Clinical TrialsFinancial ResultsLawsuitNet IncomeObesity TreatmentPharma

Published

11 Aug 2026 12:44

Catalyst

Regulatory and legal

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1783Tone

finance.yahoo.comDirect company coverage

Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay

DiabetesEarningsObesityPharmaPrice TargetPrice Target

Published

10 Aug 2026 23:20

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1861Tone

finance.yahoo.comDirect company coverage

Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and suppl

FdaManufacturingObesity DrugsPharmaRevenue GrowthShareholder

Published

10 Aug 2026 22:21

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#1967Tone

finance.yahoo.comDirect company coverage

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare's fastest-growing markets. Yet another competitive advantage for investors to keep in mind is manufacturing. During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthro

ManufacturingObesity MarketPharma

Published

10 Aug 2026 21:39

Catalyst

Macro sensitivity

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2082Tone

finance.yahoo.comDirect company coverage

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now

BiotechHealthcare

Published

10 Aug 2026 19:58

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2146Tone

finance.yahoo.comDirect company coverage

Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand: no injection. Foundayo targets GLP-1 while giving patients an oral alternative to Lilly's blockbuster Mounjaro and Zepbound. The pill entered the U.S. market in April and generated $98 m

Fda ApprovalGlp 1ObesityPharmaRevenue Outlook

Published

10 Aug 2026 19:35

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2254Tone

finance.yahoo.comDirect company coverage

Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY

During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a

Balance SheetBiotechFda ApprovalFourth QuarterHealthcareM A

Published

10 Aug 2026 18:07

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2367Tone

finance.yahoo.comDirect company coverage

Sector Update: Healthcare Stocks Rise in Afternoon Trading

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

10 Aug 2026 17:40

Catalyst

Analyst action

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2483Tone

finance.yahoo.comDirect company coverage

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

Immunocore Holdings plc IMCR offers a clear trade-off between commercial momentum and valuation risk. Kimmtrak continues to expand in metastatic uveal melanoma, while late-stage studies could open larger markets. The counterweight is equally clear. IMCR relies on one marketed product, trades above key industry valuation benchmarks and has seen a sharp deterioration in current-year earnings estimates. IMCR's Kimmtrak Growth Supports the Bull Case Second-quarter 2026 revenues rose 18.3% year over year to $115.9 million, driven by higher Kimmtrak volumes in the United States and international mar

EarningsOncologyPharmaPrice Target

Published

10 Aug 2026 15:41

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2550Tone

finance.yahoo.comDirect company coverage

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

Published

10 Aug 2026 14:12

Catalyst

Market update

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2671Tone

finance.yahoo.comDirect company coverage

Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial closing, with participation from Eli Lilly and Company ("Lilly") and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors.LifeSpan Vision Ventures Remedium is developing durable protein the

BiotechClinical DevelopmentGene TherapySeries A Financing

Published

10 Aug 2026 14:00

Catalyst

Market update

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2726Tone

finance.yahoo.comDirect company coverage

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength in non-COVID products continued to offset declining sales of its COVID products, Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower end of its 2

EarningsEarnings GrowthEarnings Per ShareObesityOncologyPatent Cliff

Published

10 Aug 2026 13:17

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2868Tone

finance.yahoo.comDirect company coverage

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

Published

10 Aug 2026 05:00

Catalyst

Market update

Evidence role

Direct company coverage

Duplicates

1 consolidated

#2935Tone

finance.yahoo.comDirect company coverage

Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced on Thursday that the service would automate eligibility checks, prior authorizations, and billing, while providing home delivery and in-store pickup to streamline access. Amazon Pharmacy will begin enrollment for eligible patients after they add their insurance and Medicare information and their clinician

Digital HealthcarePharmacyReal EstateWeight Loss

Published

10 Aug 2026 01:31

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated

#3085Tone

finance.yahoo.comDirect company coverage

Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook

Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused on how fast the obesity franchise is still expanding.Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook Bull Case: Weight Loss Demand Still Has Room To Run The headline number came from Mounjaro and Zepbound. Mounjaro revenue jumped 91% to $9.9 billion, while Zepbou

EarningsGuidanceHealthcareM AObesityRevenue Growth

Published

09 Aug 2026 08:51

Catalyst

Earnings

Evidence role

Direct company coverage

Duplicates

1 consolidated